This article explores current OSD development and manufacturing trends from a CDMO perspective, including the evolution of outsourcing, emerging technologies, manufacturing advancements and industry ...
The 340B Drug Pricing Program entitles participating hospitals and clinics (called covered entities) to purchase outpatient drugs at a substantial discount from manufacturers. Covered entities either ...
Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 millio ...
Future-ready pharma packaging must integrate connectivity, automation, and material strategy into a single, coordinated ...
According to MarketsandMarketstm, the global pharmaceutical manufacturing equipment market is projected to reach USD 21.24 billion in 2026 and USD 30.39 billion by 2032, exhibiting a CAGR of 6.2% ...
Expands Quotient's capabilities for handling and manufacturing highly potent API (HPAPI) drug molecules and products.
According to MarketsandMarkets, the global pharmaceutical manufacturing equipment market is projected to reach USD 21.24 billion in 2026 and ...
The large molecule drug substance CDMO market is projected to grow at a CAGR of approximately 9% over the forecast period.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results